{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:52:28Z","timestamp":1788562348927,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40268-020-00322-3","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T11:22:41Z","timestamp":1599736961000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nimodipine Pharmacokinetic Variability in Various Patient Populations"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-2622","authenticated-orcid":false,"given":"Sherif Hanafy","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadumo Ahmed","family":"Isse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"Cd000147","DOI":"10.1002\/14651858.Cd000147","volume":"3","author":"JM Lopez-Arrieta","year":"2002","unstructured":"Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;3:Cd000147. https:\/\/doi.org\/10.1002\/14651858.Cd000147.","journal-title":"Cochrane Database Syst Rev."},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fneur.2017.00268","volume":"8","author":"A Wessell","year":"2017","unstructured":"Wessell A, Kole MJ, Badjatia N, Parikh G, Albrecht JS, Schreibman DL, et al. High compliance with scheduled nimodipine is associated with better outcome in aneurysmal subarachnoid hemorrhage patients cotreated with heparin infusion. Front Neurol. 2017;8:268. https:\/\/doi.org\/10.3389\/fneur.2017.00268.","journal-title":"Front Neurol"},{"issue":"3","key":"322_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bja\/aes264","volume":"109","author":"MJ Rowland","year":"2012","unstructured":"Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KT. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315\u201329. https:\/\/doi.org\/10.1093\/bja\/aes264.","journal-title":"Br J Anaesth"},{"issue":"2","key":"322_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/00075198-200204000-00007","volume":"8","author":"NW Dorsch","year":"2002","unstructured":"Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care. 2002;8(2):128\u201333. https:\/\/doi.org\/10.1097\/00075198-200204000-00007.","journal-title":"Curr Opin Crit Care"},{"issue":"4","key":"322_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3171\/jns.1988.68.4.0505","volume":"68","author":"KC Petruk","year":"1988","unstructured":"Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505\u201317. https:\/\/doi.org\/10.3171\/jns.1988.68.4.0505.","journal-title":"J Neurosurg."},{"key":"322_CR6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF01456369","volume":"82","author":"J Philippon","year":"1986","unstructured":"Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. eCt ahirurgica prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien). 1986;82:110\u20134.","journal-title":"Acta Neurochir (Wien)"},{"issue":"6674","key":"322_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","volume":"298","author":"JD Pickard","year":"1989","unstructured":"Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636\u201342. https:\/\/doi.org\/10.1136\/bmj.298.6674.636.","journal-title":"BMJ"},{"issue":"11","key":"322_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm\u2013a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619\u201324. https:\/\/doi.org\/10.1056\/NEJM198303173081103.","journal-title":"N Engl J Med"},{"issue":"6","key":"322_CR9","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly","year":"2012","unstructured":"Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association\/American stroke association. Stroke. 2012;43(6):1711\u201337. https:\/\/doi.org\/10.1161\/STR.0b013e3182587839.","journal-title":"Stroke"},{"key":"322_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1527-3466.1985.tb00479.x","volume":"3","author":"A Scriabine","year":"1985","unstructured":"Scriabine A, Battye R, Hoffmeister F, Kazda S, Towart R, Garthoff B, Schl\u00fcter G, R\u00e4msch KD, Scherling D. Nimodipine. Cardiovasc Drug Rev. 1985;3:197\u201321818.","journal-title":"Cardiovasc Drug Rev"},{"issue":"5","key":"322_CR11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-198937050-00004","volume":"37","author":"L Ms","year":"1989","unstructured":"Ms L, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989;37(5):669\u201399.","journal-title":"Drugs"},{"issue":"4","key":"322_CR12","first-page":"338","volume":"32","author":"R Towart","year":"1982","unstructured":"Towart R, Wehinger E, Meyer H, Kazda S. The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung. 1982;32(4):338\u201346.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"322_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/s0022-2828(88)80128-7","volume":"20","author":"LG Herbette","year":"1988","unstructured":"Herbette LG, Trumbore M, Chester DW, Katz AM. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone. J Mol Cell Cardiol. 1988;20(5):373\u20138. https:\/\/doi.org\/10.1016\/s0022-2828(88)80128-7.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"322_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0028-3908(94)90015-9","volume":"33","author":"LG Herbette","year":"1994","unstructured":"Herbette LG, Mason PE, Sweeney KR, Trumbore MW, Mason RP. Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes. Neuropharmacology. 1994;33(2):241\u20139. https:\/\/doi.org\/10.1016\/0028-3908(94)90015-9.","journal-title":"Neuropharmacology"},{"issue":"21","key":"322_CR15","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/s0024-3205(97)00881-3","volume":"61","author":"S Uchida","year":"1997","unstructured":"Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61(21):2083\u201390. https:\/\/doi.org\/10.1016\/s0024-3205(97)00881-3.","journal-title":"Life Sci"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1749-6632.1988.tb33415.x","volume":"522","author":"A Scriabine","year":"1988","unstructured":"Scriabine A, van den Kerckhoff W. Pharmacology of nimodipine. A review. Ann N Y Acad Sci. 1988;522:698\u2013706. https:\/\/doi.org\/10.1111\/j.1749-6632.1988.tb33415.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"4","key":"322_CR17","first-page":"331","volume":"32","author":"S Kazda","year":"1982","unstructured":"Kazda S, Garthoff B, Krause HP, Schlossmann K. Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung. 1982;32(4):331\u20138.","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"322_CR18","first-page":"338","volume":"32","author":"R Towart","year":"1982","unstructured":"Towart R, Meyer H, Kazda S. The effect of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. ArzneimForsch\/Drug Res. 1982;32(1):338\u201346.","journal-title":"ArzneimForsch\/Drug Res."},{"issue":"1\u20133","key":"322_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2007.04.033","volume":"568","author":"RW Li","year":"2007","unstructured":"Li RW, Tse CM, Man RY, Vanhoutte PM, Leung GP. Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur J Pharmacol. 2007;568(1\u20133):75\u201382. https:\/\/doi.org\/10.1016\/j.ejphar.2007.04.033.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"322_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1067\/mcp.2002.128127","volume":"72","author":"P Blardi","year":"2002","unstructured":"Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther. 2002;72(5):556\u201361. https:\/\/doi.org\/10.1067\/mcp.2002.128127.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"322_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0165-6147(92)90141-r","volume":"13","author":"KA Rudolphi","year":"1992","unstructured":"Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci. 1992;13(12):439\u201345. https:\/\/doi.org\/10.1016\/0165-6147(92)90141-r.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"322_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0149-7634(96)00011-5","volume":"21","author":"MI Sweeney","year":"1997","unstructured":"Sweeney MI. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci Biobehav Rev. 1997;21(2):207\u201317. https:\/\/doi.org\/10.1016\/s0149-7634(96)00011-5.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"322_CR23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-198937050-00004","volume":"37","author":"MS Langley","year":"1989","unstructured":"Langley MS, Sorkin EM. Nimodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989;37(5):669\u201399.","journal-title":"Drugs"},{"issue":"3","key":"322_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199506030-00006","volume":"6","author":"W Muck","year":"1995","unstructured":"Muck W, Ahr G, Kuhlmann J. Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging. 1995;6(3):229\u201342.","journal-title":"Drugs Aging"},{"issue":"SUPPL. 1","key":"322_CR25","first-page":"74","volume":"28","author":"KD Ramsch","year":"1985","unstructured":"Ramsch KD, Ahr G, Tettenborn D, Auer LM. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia. 1985;28(SUPPL. 1):74\u20138.","journal-title":"Neurochirurgia"},{"issue":"5","key":"322_CR26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/j.1875-9114.1998.tb03935.x","volume":"18","author":"DK Woodward","year":"1998","unstructured":"Woodward DK, Hatton J, Ensom MH, Young B, Dempsey R, Clifton GD. Alpha1-acid glycoprotein concentrations and cerebrospinal fluid drug distribution after subarachnoid hemorrhage. Pharmacother. 1998;18(5):1062\u20138.","journal-title":"Pharmacother."},{"issue":"11","key":"322_CR27","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1080\/10826079508010268","volume":"18","author":"HR Ha","year":"2007","unstructured":"Ha HR, Pletscher W, Leuenberger PM, Sticher O, Meier PJ. Measurement of nimodipine metabolism in rat liver microsomes by high-performance liquid chromatography. J Liq Chromatogr. 2007;18(11):2243\u201355. https:\/\/doi.org\/10.1080\/10826079508010268.","journal-title":"J Liq Chromatogr"},{"issue":"4","key":"322_CR28","first-page":"392","volume":"41","author":"D Scherling","year":"1991","unstructured":"Scherling D, B\u00fchner K, Krause HP, Karl W, W\u00fcnsche C. Biotransformation of nimodipine in rat, dog, and monkey. Arzneimittelforschung. 1991;41(4):392\u20138.","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 1","key":"322_CR29","first-page":"74","volume":"28","author":"KD R\u00e4msch","year":"1985","unstructured":"R\u00e4msch KD, Ahr G, Tettenborn D, Auer LM. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia. 1985;28(Suppl 1):74\u20138.","journal-title":"Neurochirurgia"},{"key":"322_CR30","doi-asserted-by":"crossref","unstructured":"Anonymous. Population pharmacokinetic analysis for nimodipine. Jpn J Clin Pharmacol Ther. 1999;30(1):229\u201330. https:\/\/www.jstage.jst.go.jp\/article\/jscpt1970\/30\/1\/30_1_229\/_pdf\/-char\/en.","DOI":"10.3999\/jscpt.30.229"},{"issue":"6","key":"322_CR31","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/0014-2999%2890%2993850-P","volume":"183","author":"C Becker","year":"1990","unstructured":"Becker C, Hilgert D, Platt D, Krauss D, Spahn H, Mutschler E. Pharmacokinetics of nimodipine and its major metabolites in elderly patients with cerebral disorders. Eur J Pharmacol. 1990;183(6):2298. https:\/\/doi.org\/10.1016\/0014-2999%2890%2993850-P.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"322_CR32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jps.2600820305","volume":"82","author":"C Fischer","year":"1993","unstructured":"Fischer C, Schonberger F, Muck W, Heuck K, Eichelbaum M. Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography\/mass spectroscopy combined with a stable isotope technique. J Pharm Sci. 1993;82(3):244\u201350.","journal-title":"J Pharm Sci"},{"issue":"8","key":"322_CR33","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1167\/iovs.05-1350","volume":"47","author":"G Michelson","year":"2006","unstructured":"Michelson G, W\u00e4rntges S, Leidig S, L\u00f6tsch J, Geisslinger G. Nimodipine plasma concentration and retinal blood flow in healthy subjects. Invest Ophthalmol Vis Sci. 2006;47(8):3479\u201386.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"322_CR34","first-page":"89","volume":"33","author":"W Muck","year":"1995","unstructured":"Muck W, Heine PR, Breuel HP, Niklaus H, Horkulak J, Ahr G. The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. Int J Clin Pharmacol Ther. 1995;33(2):89\u201394.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"322_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/1520-636X%282000%2912:9%3C660::AID-CHIR3%3E3.0.CO;2-1","volume":"12","author":"H Wanner-Olsen","year":"2000","unstructured":"Wanner-Olsen H, Gaarskaer FB, Mikkelsen EO, Jakobsen P, Voldby B. Studies on concentration-time profiles of nimodipine enantiomers following intravenous and oral administration of nimodipine in patients with subarachnoid hemorrhage. Chirality. 2000;12(9):660\u20134. https:\/\/doi.org\/10.1002\/1520-636X%282000%2912:9%3C660:AID-CHIR3%3E3.0.CO;2-1.","journal-title":"Chirality"},{"issue":"7","key":"322_CR36","first-page":"293","volume":"34","author":"W Muck","year":"1996","unstructured":"Muck W, Kuhlmann J. The influence of age on pharmacokinetics of nimodipine*. Int J Clin Pharmacol Ther. 1996;34(7):293\u20138.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"3","key":"322_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0167-4943%2892%2990030-8","volume":"14","author":"H Eicher","year":"1992","unstructured":"Eicher H, Hilgert D, Zeeh J, Platt D, Becker C, Mutschler E. Pharmacokinetics of nimodipine in multimorbid elderly patients with chronic brain failure. Arch Gerontol Geriatr. 1992;14(3):309\u201319. https:\/\/doi.org\/10.1016\/0167-4943%2892%2990030-8.","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"322_CR38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00607954","volume":"30","author":"E Vinge","year":"1986","unstructured":"Vinge E, Andersson KE, Brandt L, Ljunggren B, Nilsson LG, Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"322_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2017.03.062","author":"W Albanna","year":"2017","unstructured":"Albanna W, Weiss M, Conzen C, Clusmann H, Schneider T, Reinsch M, et al. Systemic and cerebral concentration of nimodipine during established and experimental vasospasm treatment. World Neurosurg. 2017. https:\/\/doi.org\/10.1016\/j.wneu.2017.03.062.","journal-title":"World Neurosurg"},{"issue":"5","key":"322_CR40","first-page":"381","volume":"4","author":"W Kirch","year":"1984","unstructured":"Kirch W, R\u00e4msch KD, D\u00fchrsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res. 1984;4(5):381\u20134.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"8","key":"322_CR41","first-page":"404","volume":"37","author":"D Terziivanov","year":"1999","unstructured":"Terziivanov D, Atanasova I, Dimitrova V, Robeva R, Unger S, M\u00fcck W. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. Int J Clin Pharmacol Ther. 1999;37(8):404\u201312.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"322_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.1987.tb03008.x","volume":"23","author":"FM Gengo","year":"1987","unstructured":"Gengo FM, Fagan SC, Krol G, Bernhard H. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol. 1987;23(1):47\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"322_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JNN.0000000000000464","volume":"51","author":"SH Peacock","year":"2019","unstructured":"Peacock SH, James C, Turnbull MT, Cowart JB, Reid JM, Freeman WD. Pharmacogenomics of cytochrome P450 of nimodipine metabolism after aneurysmal subarachnoid hemorrhage. J Neurosci Nurs. 2019;51(5):238\u201342. https:\/\/doi.org\/10.1097\/JNN.0000000000000464.","journal-title":"J Neurosci Nurs"},{"issue":"6","key":"322_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00228-009-0619-6","volume":"65","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Zhai D, He H, Li T, Chen X, Ji H. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol. 2009;65(6):579\u201384. https:\/\/doi.org\/10.1007\/s00228-009-0619-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"322_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2217\/pgs-2019-0136","volume":"21","author":"CL James","year":"2020","unstructured":"James CL, Turnbull MT, Freeman WD. Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage. Pharmacogenomics. 2020;21(6):387\u201392. https:\/\/doi.org\/10.2217\/pgs-2019-0136.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"322_CR46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.1991.tb03908.x","volume":"32","author":"A Tartara","year":"1991","unstructured":"Tartara A, Galimberti CA, Manni R, Parietti L, Zucca C, Baasch H, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991;32(3):335\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"322_CR47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-007-0267-7","volume":"63","author":"V Soppi","year":"2007","unstructured":"Soppi V, Kokki H, Koivisto T, Lehtonen M, Helin-Tanninen M, Lehtola S, et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage\u2014a pilot study. Eur J Clin Pharmacol. 2007;63(4):355\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"322_CR48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00266356","volume":"42","author":"W M\u00fcck","year":"1992","unstructured":"M\u00fcck W, Wingender W, Seiberling M, Woelke E, R\u00e4msch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"322_CR49","first-page":"126","volume":"36","author":"U Fuhr","year":"1998","unstructured":"Fuhr U, Maier-Br\u00fcggemann A, Blume H, M\u00fcck W, Unger S, Kuhlmann J, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126\u201332.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"322_CR50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.1552-4604.1994.tb02048.x","volume":"34","author":"JC Fleishaker","year":"1994","unstructured":"Fleishaker JC, Hulst LK, Peters GR. Lack of a pharmacokinetic\/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. J Clin Pharmacol. 1994;34(8):837\u201341.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"322_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.1994.tb04319.x","volume":"38","author":"PR Heine","year":"1994","unstructured":"Heine PR, Weyer G, Breuel HP, Muck W, Schmage N, Kuhlmann J. Lack of interaction between diazepam and nimodipine during chronic oral administration to healthy elderly subjects. Br J Clin Pharmacol. 1994;38(1):39\u2013433.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"322_CR52","first-page":"103","volume":"33","author":"HP Breuel","year":"1995","unstructured":"Breuel HP, Heine PR, M\u00fcck W, Niklaus H, Schmage N, Kuhlmann J. Chronic administration of nimodipine and propranolol in elderly normotensive subjects\u2013an interaction study. Int J Clin Pharmacol Ther. 1995;33(2):103\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"322_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1742-7843.2011.00722.x","volume":"109","author":"S Bruderer","year":"2011","unstructured":"Bruderer S, Zisowsky J, Fuseau E, Gutierez M, Dingemanse J. Investigation of pharmacokinetic and pharmacodynamic interactions between clazosentan and nimodipine in asah patients: a population analysis. Basic Clin Pharmacol Toxicol. 2011;109:150. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00722.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"322_CR54","first-page":"460","volume":"45","author":"W M\u00fcck","year":"1995","unstructured":"M\u00fcck W, Heine PR, Schmage N, Niklaus H, Horkulak J, Breuel HP. Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. Arzneimittelforschung. 1995;45(4):460\u20132.","journal-title":"Arzneimittelforschung"},{"key":"322_CR55","unstructured":"NIMOTOP\u00aePRODUCT MONOGRAPH M, Ontario, 2014, Bayer Inc."},{"key":"322_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00228-007-0267-7","volume":"63","author":"V Soppi","year":"2007","unstructured":"Soppi V, Kokki H, Koivisto T, Lehtonen M, Helin-Tanninen M, Lehtola S, et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage\u2014a pilot study. Eur J Clin Pharmacol. 2007;63:355\u201361. https:\/\/doi.org\/10.1007\/s00228-007-0267-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"322_CR57","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00701-015-2369-9","volume":"157","author":"T Abboud","year":"2015","unstructured":"Abboud T, Andresen H, Koeppen J, Czorlich P, Duehrsen L, Stenzig J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157(5):763\u20137. https:\/\/doi.org\/10.1007\/s00701-015-2369-9.","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"322_CR58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00265956","volume":"45","author":"CR Kumana","year":"1993","unstructured":"Kumana CR, Kou M, Yu YL, Fong KY, Fung CF, Chang CM, et al. Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. Eur J Clin Pharmacol. 1993;45(4):363\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"322_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18433\/jpps30960","volume":"23","author":"FA Isse","year":"2020","unstructured":"Isse FA, Abdallah YEH, Mahmoud SH. The impact of nimodipine administration through feeding tube on outcomes in patients with aneurysmal subarachnoid hemorrhage. J Pharm Pharm Sci. 2020;23(1):100\u20138. https:\/\/doi.org\/10.18433\/jpps30960.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"322_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","volume":"15","author":"MN Diringer","year":"2011","unstructured":"Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211\u201340. https:\/\/doi.org\/10.1007\/s12028-011-9605-9.","journal-title":"Neurocrit Care."},{"issue":"6","key":"322_CR61","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/clpt.2008.62","volume":"83","author":"VD Schmith","year":"2008","unstructured":"Schmith VD, Foss JF. Effects of inflammation on pharmacokinetics\/pharmacodynamics: increasing recognition of its contribution to variability in response. Clin Pharmacol Ther. 2008;83(6):809\u201311. https:\/\/doi.org\/10.1038\/clpt.2008.62.","journal-title":"Clin Pharmacol Ther"},{"key":"322_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000356","author":"R Riva","year":"2019","unstructured":"Riva R, Pegoli M, Contin M, Perrone A, Mohamed S, Zanello M. Cerebrospinal fluid concentrations of nimodipine correlate with long-term outcome in aneurysmal subarachnoid hemorrhage: pilot study. Clin Neuropharmacol. 2019. https:\/\/doi.org\/10.1097\/WNF.0000000000000356.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"322_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.NAJ.0000391235.60640.da","volume":"110","author":"DS Aschenbrenner","year":"2010","unstructured":"Aschenbrenner DS. Oral nimodipine given intravenously can be fatal. AJN Am J Nurs. 2010;110(12):27. https:\/\/doi.org\/10.1097\/01.NAJ.0000391235.60640.da.","journal-title":"AJN Am J Nurs"},{"issue":"1\u20132","key":"322_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.wneu.2011.09.030","volume":"78","author":"V Soppi","year":"2012","unstructured":"Soppi V, Karamanakos PN, Koivisto T, Kurki MI, Vanninen R, Jaaskelainen JE, et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78(1\u20132):101\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2011.09.030.","journal-title":"World Neurosurg"},{"issue":"1","key":"322_CR65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3171\/2008.7.JNS08178","volume":"110","author":"E Kronvall","year":"2009","unstructured":"Kronvall E, Undren P, Romner B, Saveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg. 2009;110(1):58\u201363. https:\/\/doi.org\/10.3171\/2008.7.JNS08178.","journal-title":"J Neurosurg"},{"issue":"4","key":"322_CR66","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/STROKEAHA.119.027396","volume":"51","author":"AP Carlson","year":"2020","unstructured":"Carlson AP, Hanggi D, Wong GK, Etminan N, Mayer SA, Aldrich F, et al. Single-dose intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke. 2020;51(4):1142\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027396.","journal-title":"Stroke"},{"issue":"2","key":"322_CR67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/106002809603000208","volume":"30","author":"AJ Carcas","year":"1996","unstructured":"Carcas AJ, Abad-Santos F, De Rosendo JM, Frias J. Nimodipine transfer into human breast milk and cerebrospinal fluid. Ann Pharmacother. 1996;30(2):148\u201350.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"322_CR68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/bja\/74.5.526","volume":"74","author":"M Hynynen","year":"1995","unstructured":"Hynynen M, Siltanen T, Sahlman A, Pohjasvaara T, Muck W, Kaste M. Continuous infusion of nimodipine during coronary artery surgery: haemodynamic and pharmacokinetic study. Br J Anaesth. 1995;74(5):526\u201333.","journal-title":"Br J Anaesth"},{"issue":"2","key":"322_CR69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0378-4347(00)83296-X","volume":"374","author":"P Jakobsen","year":"1986","unstructured":"Jakobsen P, Mikkelsen EO, Laursen J, Jensen F. Determination of nimodipine by gas chromatography using electron-capture detection; External factors influencing nimodipine concentrations during intravenous administration. J Chromatogr Biomed Appl. 1986;374(2):383\u20137.","journal-title":"J Chromatogr Biomed Appl"},{"issue":"SUPPL. 1","key":"322_CR70","first-page":"73","volume":"6","author":"KD Ramsch","year":"1986","unstructured":"Ramsch KD, Graefe KH, Scherling D. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol. 1986;6(SUPPL. 1):73\u201380.","journal-title":"Am J Nephrol"},{"issue":"3","key":"322_CR71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0032-1313724","volume":"73","author":"C Scheller","year":"2012","unstructured":"Scheller C, Vogel AS, Simmermacher S, Rachinger JC, Prell J, Strauss C, et al. Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspects. J Neurol Surg Part A Central Eur Neurosurg. 2012;73(3):153\u20139. https:\/\/doi.org\/10.1055\/s-0032-1313724.","journal-title":"J Neurol Surg Part A Central Eur Neurosurg"},{"issue":"2","key":"322_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-0033-1337608","volume":"75","author":"C Scheller","year":"2014","unstructured":"Scheller C, Wienke A, Wurm F, Vogel AS, Simmermacher S, Prell J, et al. Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study. J Neurol Surg Part A Central Eur Neurosurg. 2014;75(2):84\u201390. https:\/\/doi.org\/10.1055\/s-0033-1337608.","journal-title":"J Neurol Surg Part A Central Eur Neurosurg"},{"issue":"2","key":"322_CR73","first-page":"100","volume":"3","author":"WI Steudel","year":"1989","unstructured":"Steudel WI, Carvi M, Lorenz R. Prognostic significance of the concentration of nimodipine in the CSF and plasma in acute subarachnoid hemorrhage. New Trends Clin Neuropharmacol. 1989;3(2):100.","journal-title":"New Trends Clin Neuropharmacol"},{"issue":"10","key":"322_CR74","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1177\/106002809402801001","volume":"28","author":"JJ Sramek","year":"1994","unstructured":"Sramek JJ, Heller AH, Sundaresan PR, Lettieri J, Sawin S, Cutler NR. Safety and tolerance of intravenous nimodipine. Ann Pharmacother. 1994;28(10):1143\u20138. https:\/\/doi.org\/10.1177\/106002809402801001.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"322_CR75","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00044011-199917060-00008","volume":"17","author":"V Gualano","year":"1999","unstructured":"Gualano V, Ntsikoussalabongui B, Mignot A, Duvauchelle T, Felices M, Guillaume M, et al. Comparative bioavailability of two oral nimodipine formulations after administration to 24 healthy volunteers. Clin Drug Investig. 1999;17(6):475\u201382. https:\/\/doi.org\/10.2165\/00044011-199917060-00008.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"322_CR76","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejps.2003.11.009","volume":"21","author":"Z He","year":"2004","unstructured":"He Z, Zhong D, Chen X, Liu X, Tang X, Zhao L. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci. 2004;21(4):487\u201391.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"322_CR77","first-page":"25","volume":"10","author":"XD Liu","year":"1996","unstructured":"Liu XD, Xie L, Xu GQ, Wang J, Zhou YC, Liu GQ. Variability of nimodipine pharmacokinetics in healthy Chinese males. Chin J Pharmacol Toxicol. 1996;10(1):25\u20137.","journal-title":"Chin J Pharmacol Toxicol"},{"issue":"4","key":"322_CR78","first-page":"163","volume":"34","author":"W Muck","year":"1996","unstructured":"Muck W, Tanaka T, Ahr G, Kuhlmann J. No interethnic differences in stereoselective disposition of oral nimodipine between Caucasian and Japanese subjects. Int J Clin Pharmacol Ther. 1996;34(4):163\u201371.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"322_CR79","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jpba.2007.10.035","volume":"46","author":"F Qin","year":"2008","unstructured":"Qin F, Ma Y, Wang Y, Chen L, Wang D, Li F. Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2008;46(3):557\u201362. https:\/\/doi.org\/10.1016\/j.jpba.2007.10.035.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"322_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jchromb.2003.12.001","volume":"802","author":"F Qiu","year":"2004","unstructured":"Qiu F, Chen X, Li X, Zhong D. Determination of nimodipine in human plasma by a sensitive and selective liquid chromatography-tandem mass spectrometry method. J Chromatogr B Anal Technol Biomed Life Sci. 2004;802(2):291\u20137. https:\/\/doi.org\/10.1016\/j.jchromb.2003.12.001.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"2","key":"322_CR81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/chromsci\/48.2.81","volume":"48","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Zhai D, Chen X, Yu Q, He H, Sun Y, et al. Determination of nimodipine in human plasma by HPLC-ESI-MS and its application to a bioequivalence study. J Chromatogr Sci. 2010;48(2):81\u20135.","journal-title":"J Chromatogr Sci"},{"issue":"2","key":"322_CR82","first-page":"109","volume":"33","author":"HP Breuel","year":"1995","unstructured":"Breuel HP, Muck W, Heine PR, Schmage N, Niklaus H, Kuhlmann J. The influence of nimodipine on hemodynamic parameters and peak and trough plasma concentrations of nifedipine chronically administered to elderly hypertensive patients. Int J Clin Pharmacol Ther. 1995;33(2):109\u201313.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"322_CR83","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1038\/sj.jhh.1001361","volume":"16","author":"R Hern\u00e1ndez-Hern\u00e1ndez","year":"2002","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez R, Coll T, Rachitzky P, Armas-Hern\u00e1ndez MJ, Armas-Padilla MC, Velasco M, et al. Comparison of two nimodipine formulations in healthy volunteers. J Hum Hypertens. 2002;16(Suppl 1):S142\u2013S144144.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"322_CR84","first-page":"381","volume":"4","author":"W Kirch","year":"1984","unstructured":"Kirch W, Ramsch KD, Duhrsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res. 1984;4(5):381\u20134.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"7","key":"322_CR85","first-page":"293","volume":"34","author":"W Muck","year":"1996","unstructured":"Muck W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol Ther. 1996;34(7):293\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"322_CR86","first-page":"460","volume":"45","author":"W Muck","year":"1995","unstructured":"Muck W, Heine PR, Schmage N, Niklaus H, Horkulak J, Breuel HP. Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. Arzneimittel-Forschung\/Drug Res. 1995;45(4):460\u20132.","journal-title":"Arzneimittel-Forschung\/Drug Res"},{"issue":"8","key":"322_CR87","first-page":"404","volume":"37","author":"D Terziivanov","year":"1999","unstructured":"Terziivanov D, Atanasova I, Dimitrova V, Robeva R, Unger S, Muck W. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. Int J Clin Pharmacol Ther. 1999;37(8):404\u201312.","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00322-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T14:59:59Z","timestamp":1723561199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00322-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00322-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"9 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no funding associated with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval required for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}